'
University of Exeter partners with mHealth provider Monsenso in dementia research project.

University of Exeter partners with mHealth provider Monsenso in dementia research project.

Copenhagen, Denmark – 25 March 2019. The University of Exeter, supported by the South West Academic Health Science Network, has partnered with Danish mobile health provider Monsenso in ‘The MOVE Study’ (formerly known as The Klick Project), a research project that aims to review how the Monsenso Solution can be used to support individuals to engage in healthy behaviours that could make a difference to their risk of getting dementia. The Monsenso Solution is a mobile platform, where the individual is prompted with daily self-assessments, weekly clinical scales, while sensor data is collected via the phone. Moreover, it connects the individual and clinician, visualising individual-reported data for both parties and facilitates the possibility of providing patients with relevant information to handle specific challenges that may impact their wellbeing.

Both from a societal and a clinical standpoint, the burden of dementia is a growing challenge. The number of people affected by dementia worldwide will reach 75 million people in 2030. In the UK, for example, Dementia UK estimated that approximately 850,000 people were living with dementia[1]. In addition, it was estimated that one in three people born in 2015 will develop dementia in their lifetime[2]. Therefore, new ways of tackling this challenge must be found.

In collaboration with Monsenso, the lead researchers on The MOVE Study – Dr Barbora Silarova and Dr Rachel Collins will set up the solution to support The MOVE Study, and hereafter demonstrate its capabilities for clinicians and patients and receive their feedback. The findings will be used to guide development of future intervention that focuses on changing healthy behaviours that could make a difference to people’s risk of getting dementia. It is planned for the intervention to be delivered in primary care. The configuration of the Monsenso Solution for The MOVE Study will include one of the newest additions to the system; an integration to Withings (wearable technology) which allows for collection of sensor data, such as physical activity, sleep and pulse.

Thomas Lethenborg, CEO of Monsenso, says: “Dementia is a huge challenge for society to overcome, and it will be growing in the coming years due to an ageing population. We are looking forward to testing whether our solution can help people to engage in healthy behaviours to live a healthy life. We may draw on experiences gained from the H2020 funded WellCo project, which aims at improving the well-being of elderly people.”

About University of Exeter

University of Exeter combines teaching excellence and high levels of student satisfaction with world class research at their campuses in Devon and Cornwall. They are part of the Russell Group as one of the 24 leading UK universities. Their success is built on a strong partnership with their students and a clear focus on high performance.

For more information about dementia research conducted at University of Exeter, please see http://www.exeter.ac.uk/dementia/.

About South West Academic Health Science Network

The South West Academic Health Science Network (SW AHSN) works to improve the health and patient experience of people in the South West by supporting and accelerating innovation and quality improvement. SW AHSN is part of a national network of 15 AHSNs set up by NHS England, to identify, adopt and disseminate innovative healthcare. As part of KLICK, they will be aiding in the conversation and co-design of solutions to better meet patient needs by bringing together innovators and adopters of new ideas for health and social care.

To learn more, visit https://www.swahsn.com/.

About Monsenso

Monsenso is an innovative technology company offering a mHealth solution that optimises the treatment of mental disorders. The smartphone-based solution gives a detailed overview of an individual’s mental health through the collection of outcome, adherence and behavioural data, and it connects individuals, carers and health care providers enabling personalised treatment, remote care and early intervention.

To learn more, visit www.monsenso.com

For more information about Monsenso contact:

Thomas Lethenborg
CEO
Monsenso 
+45 21298827
lethenborg@monsenso.com


[1] Dowrick, A., Southern, A. . Dementia 2014: Opportunity for change. 2014  17/10/2018]; Available from: https://www.alzheimers.org.uk/sites/default/files/migrate/downloads/dementia_2014_opportunity_for_change.pdf.

[2] Lee, V.S., J. Simpson, and K. Froggatt, A narrative exploration of older people’s transitions into residential care. Aging Ment Health, 2013. 17(1): p. 48-56.

Improve the way you work with your mental health patients

Improve the way you work with your mental health patients

Copenhagen, Denmark – 28 February 2019. Mobile health technology can be used to support important decision making in diagnosis and treatment, especially in the field of mental health. It can empower patients by involving them in their own treatment and by providing them with the tools needed to help them manage their own disorder. Monsenso is leading the way in making technology an integral and useful part of mental health treatment.

. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

Imagine a session with your patient in which you have an overall picture of their mood, sleep, and medication adherence and can ask questions relating to their current mental state.  You can view patient self-assessment data that will give you a better idea of how they have been doing day-to-day, giving you a better understanding of their mood over time. With this, your questions in the session can be more relevant, and you can more quickly identify important topics.

What you just read is a possibility when taking advantage of today’s technology. In the Monsenso app, patients are asked to fill out a quick, daily self-assessment or weekly questionnaires. They may for instance be asked to rate their sleep, mood or activity. They will be able to follow their own progress and become more aware of how the choices they make impact their mental state. What is more is that you can see exactly what your patients input through accessing the clinical web-portal. This knowledge can help you in the process of diagnosing or finding the most effective medication for an individual more quickly. Clinicians using the system say that the solution can be compared to a “mental X-ray,” which may even allow you to do early interventions, as you can see which patients are beginning to experience a negative state or even a relapse.

One healthcare professional who uses the Monsenso solution says: “During conversations with my patients, I always start with the data in the system. It is a great icebreaker that allows me to skip asking certain questions. Now, our conversations are facilitated by the information available in the system.”

The Monsenso solution empowers patients to be more involved in their own treatment. In between sessions they may use relevant features when they are facing a challenging situation, whether it is restructuring negative thoughts using our mobile CBT thought feature or learning more about their disorder or treatment plan in the psychoeducation library.

A patient living with bipolar disorder finds the solution beneficial in managing their disorder: “It made me more aware of how my sleep pattern influences my mood. In my life with this disorder I see myself as a tightrope walker, and this metaphor for living with bipolar disorder is very meaningful. You have to prevent losing control either to depression or to mania. You are able to avoid that by earlier registration on how your mood is fluctuating, so therefore the app helps to keep you in control of your life…”

We believe it is time for technology to ease the burden on clinicians and provide opportunities that are not available when everything is handled in the old paper-pencil way. If you too think technology needs to become more widely used in the treatment and is ready to embrace it, Monsenso will be there helping you all the way.

Want to know more? You are more than welcome to visit www.monsenso.com, or e-mail any questions to mankhong@monsenso.com.

Leading Danish addiction treatment center, KABS, enhances treatment services with data-driven mobile health technology

Leading Danish addiction treatment center, KABS, enhances treatment services with data-driven mobile health technology

Copenhagen, Denmark – 30 January 2019. The management of Copenhagen-based KABS acknowledges that there is a need to digitise parts of the treatment to both ease the burden of difficult and time consuming data collection and to offer people better, more proactive and personalised treatment. Therefore, Monsenso and KABS have joined forces to provide more effective, user-centered treatment by using mobile health technology to better support people struggling with addiction.

“Knowing about the individual’s well-being is crucial for setting up the best possible treatment. Gathering data solely through face-to-face interviews might often be inaccurate and time consuming, and the data may be biased by the individuals’ well-being and motivations during each interview session. We have decided to use the Monsenso solution, to improve our data collection using a digital platform for individuals to do self-assessments. By knowing more about the individuals, we are able to provide better treatment, while it is also an attempt to reach and attract the young people, who are in need of help.” says Rasmus Axelsson, Head of KABS.

The Monsenso solution will be implemented in a pilot project in the unit KABS Stjernevang with 10 therapists using the system. The pilot project includes both alcohol and substance abuse, as well as cases of comorbidity, where individuals also suffer from a mental illness. The mHealth solution combines data collection through self-assessments and questionnaires to provide the therapists with a detailed longitudinal view of the person’s wellbeing.

The Monsenso solution will be customised to complement KABS’ services in order to provide therapists with an overview of the individual’s illness progression, their symptoms and any medication compliance. The solution also notifies therapists and users when they display any illness related warning signs, enabling them to monitor each user remotely and to intervene at an early stage.

“We are looking forward to be working with KABS and the experienced team of therapists. We understand the very close relationship between mental health and addiction and are working closely with Rasmus and his Team to enhance the way alcohol and substance abuse treatment is delivered.” said Thomas Lethenborg, CEO of Monsenso.

Click here to read the press release in Danish.

About KABS

KABS is part of Glostrup Municipality and is one of the largest addiction treatment centers in Denmark, and has provided medical treatment and therapy for substance and alcohol abuse for many years. The organisation currently provides medical and social treatment for substance and alcohol abuse to approximately 800 citizens from 46 municipalities.

To learn more, visit https://www.kabs.dk/

About Monsenso

Monsenso is an innovative technology company offering a mHealth solution that optimises the treatment of mental disorders. The smartphone-based solution gives a detailed overview of an individual’s mental health through the collection of outcome, adherence and behavioural data, and it connects individuals, carers and health care providers enabling personalised treatment, remote care and early intervention.

To learn more, visit www.monsenso.com

For more information about Monsenso contact:

Thomas Lethenborg
CEO
Monsenso
+45 21298827
lethenborg@monsenso.com

Municipality of Ikast-Brande strengthens its addiction services with Monsenso

Municipality of Ikast-Brande strengthens its addiction services with Monsenso

Copenhagen, Denmark – 17 January 2019. Monsenso, a Danish healthtech company focused on mobile health solutions for mental health, is proud to announce our newest collaboration with the Center for Rusmiddelbehandling in the municipality of Ikast-Brande. The aim of the pilot project is to examine how the Monsenso mhealth solution can be used as an integrated part of the addiction treatment, across both alcohol and substance misuse.

The project, which will be running from January 2019 to January 2020, will primarily involve people in outpatient treatment. This is the first step in implementing the solution more broadly throughout the center’s services, widening the scope and population that they can reach, and ultimately benefitting the people living in the municipality.

The aim of the project is to evaluate the clinical and financial benefits of using the Monsenso Solution. This is relevant for clients currently receiving treatment and for clients who have completed their treatment and are part of the post-treatment service, where it is crucial not to fall back into old and undesired habits.

With the help of the Monsenso solution and the data that are being reported directly by the client, the clinician will be able to personalise the treatment to fit each client’s needs, as they have knowledge of the client’s issues over time. It also allows for clinicians to be more proactive and reach out to clients at the time they need help in order to avoid potential relapses.

Thomas Lethenborg, CEO of Monsenso ApS, says: “The Center for Rusmiddelbehandling in Ikast-Brande strives to enhance the quality of their services by implementing the newest technology. Addiction services are an interesting growth area for Monsenso, and we are convinced that implementing our solution will be beneficial to both clients and clinicians. Moreover, the collected data are opening up a number of exciting and innovative opportunities relating to addiction treatment.”

Mette Christensen, the Head of the Center for Rusmiddelbehandling, says: “We are implementing this new technology in our addiction services to improve the quality of the treatment we can provide. At the same time, we get to be more pro-active and understand our clients better, which will profit both them and the entire municipality. The clinicians are motivated to try a different working method, so we look forward to getting started”.

Click here to read the press release in Danish.


About Center for Rusmiddelbehandling
Center for Rusmiddelbehandling (CFR) is Ikast-Brande municipality’s offer of counselling, treatment and prevention of alcohol and substance misuse. The center currently has 20 employees with different educational backgrounds, which provides a wide range of competences. CFR offers both outpatient alcohol and substance treatment, day treatment and substitution therapy.
For more information visit www.cfr.ikast-brande.dk.

About Monsenso
Monsenso is an innovative technology company offering a mHealth solution that optimises the treatment of mental disorders. Our mission is to help individuals, carers, caregivers and researchers to overcome the burden of mental illness. The solution provides a detailed overview of an individual’s mental health through self-monitoring and collection of behavioural data and supports the individual by connecting them to carers and clinicians to facilitate self-care, informal and formal care. Our team is committed to developing extensive solutions that effortlessly fit into the lives of the individuals and support the treatment resulting in a better mental health.
For more information visit www.monsenso.com.

For further information about Monsenso contact:
Thomas Lethenborg
CEO
Monsenso
+45 21298827
Lethenborg@monsenso.com

Monsenso partnered with University of Cambridge to support research into individuals with intellectual disabilities

Monsenso partnered with University of Cambridge to support research into individuals with intellectual disabilities

Monsenso has partnered with the University of Cambridge, Department of Psychiatry, to support the research of using mHealth to help identify the possible causes of behavioural problems for those with intellectual disabilities.

The University plans to further their research and advance their understanding of behavioural problems in individuals with intellectual disabilities, which will initially include a  group of people with Prader-Willi Syndrome. The study will be focusing on recording of information & data relating to their mental health state and try to elucidate the reasons for the behavioural problems.

Professor Tony Holland, Chair in Learning Disabilities in the Department of Psychiatry at the University of Cambridge said: “In the field of learning disabilities, we are asking questions like: “How do we detect poor mental health and behavioural problems early on?” By applying new technological solutions, such as Monsenso, we can not only improve how we collect data, but also how we can identify signatures that are an indication of poor mental health and behavioural problems.”

The Monsenso mHealth solution is used in a growing number of mental health innovation and research related studies. Monsenso is delighted to be working with Prof. Holland and team. The solution will be employed to monitor individuals and collect behavioural and physiological data via the smartphone delivered solution. The solution will collect daily self-assessment data, diary entries and record physiological measures, complemented by passive data collection by both the smartphone and wearable devices. This aim of the study is to use this data to determine the effectiveness of treatment on a number of physiological measures, and to compare physiological measures between groups of participants. Additionally, this study also wishes to see if this data can potentially identify triggers, or causes, of the behavioural problems of participants.

In previous similar research studies, clinicians, nurses and researchers were also asked to collect data about the client’s mental state and outbursts. However, this data was pen-and-paper based, which was clearly vulnerable to inaccuracies, as it was dependent upon the nurse’s ability to remember and record the events as soon as they occurred. It was also difficult for these notes to provide a longitudinal picture of the client’s behaviour over time. Applience of the technological solutions is a massive advancement in how researchers utilise and collect research data in this complex setting.

“Research is essential to find out which treatment and interventions work better for the patients and our mHealth solution can be used to enhance data collection and outcome measures that support this. Using this technology, Monsenso can help provide a detailed longitudinal overview about the individual’s mental state, which can help to identify signatures of behavioural patterns, and even forecast future conditions. We are proud to support the researchers of the University of Cambridge”, says Thomas Lethenborg, CEO of Monsenso.

Harnessing mHealth with addiction at Amy’s Place

Harnessing mHealth with addiction at Amy’s Place

This is the reposting of an original article written by Centra Group. You can read the original article here.

Monsenso is proud to announce a new working partnership with UK’s telecare provider, Centra. The joint work will explore new, digital approaches to mental health service provision at Amy’s Place’ – Centra’s and Amy Winehouse Foundation’s (AWF) flagship addiction recovery service in East London.

The Monsenso mHealth app offers a comprehensive solution for managing a range of affective disorders, including depression, bipolar disorder, schizophrenia and borderline personality disorder. By utilising everyday smartphone technology, Monsenso supports individuals to self-manage their conditions whilst providing valuable insights to their mental health or social care support worker.

The Monsenso solution combines self-reported data and environmental sensor data to provide a balanced view of an individual’s behaviour and mood over time. The data can be accessed by nominated support staff to help inform diagnosis and treatment pathways.

Over the past ten months Centra’s Research and Innovation (R&I) team has worked closely with Monsenso as well as staff and residents at Amy’s Place to evaluate and configure the solution.

A pilot program will be established for six months, with testing conducted by a group of young women currently living at Amy’s Place and their support workers. Throughout the pilot, the service will be evaluated and supported by Centra’s R&I team to ensure that it meets expectations and maximises its benefits..

About Centra

Centra is one of UK’s largest providers of telecare services delivering a range of life-saving alarm and monitoring services to social care workers, housing associations, health professionals, local authorities and individuals. Supporting over 100,000 customers across the country, our aim is to help people live safely and independently for longer. Our in-house Telecare team provide 24/7 call monitoring and support our clients with wellbeing checks, automated “I’m OK” calls and scheduled medication reminders. We also offer GPS-enabled devices for round-the-clock support away from home. As industry leaders, we provide cutting-edge technology solutions and tailored support that help meet customers’ ever-changing needs. To learn more, visit www.centragroup.org.uk

About Monsenso

Monsenso is an innovative technology company offering a mHealth solution that optimises the treatment of mental disorders. Our mission is to help individuals, carers, healthcare providers and researchers overcome the burden of mental illness. Our solution provides a detailed overview of an individual’s mental health through the collection of behavioural data and self-monitoring, and by connecting individuals, carers and health care providers it supports self-care, informal care as well as formal treatment. Based on continued research and development, our team is committed to developing comprehensive solutions that fit seamlessly into the lives of individuals, increasing the quality and efficacy of their mental health and treatment. To learn more, visit www.monsenso.com

About the Amy Winehouse Foundation

The Amy Winehouse Foundation works to prevent the effects of drug and alcohol misuse on young people. We also aim to support, inform and inspire vulnerable and disadvantaged young people to help them reach their full potential. We are driven by a powerful vision for young people, a world where young people can flourish. To learn more, visit www.amywinehousefoundation.org